EU Approval for Vision-Restoring Chip Raises Questions About Access and Equity

The European Union’s medical device regulator has approved Science Corporation’s PRIMA device, a cutting-edge technology that restores vision lost from age-related macular degeneration (AMD). The device uses a hybrid of silicon chips and living cells to transmit a view of the world via camera-equipped glasses.

Millions worldwide suffer from AMD, with an estimated 10 million people in the United States alone living with some form of macular degeneration. While PRIMA promises functional vision to those who have lost it, its price tag – expected to be in the hundreds of thousands of dollars per unit – makes it inaccessible to all but a select few.

Science Corporation’s founder and CEO, Max Hodak, has stated that building a sustainable business is crucial for developing longer-term technologies. He believes that restoring vision will finance more ambitious projects, such as directly implanted bio-hybrid brain sensors. However, this approach may appease investors but does little to address the issue of affordability.

The European approval process was swift, with Science Corporation stating that PRIMA received a designation from the US Food and Drug Administration (FDA) that paves the way for an expedited regulatory review. This is a significant step forward, but it’s essential to examine the broader implications of such technologies on healthcare systems worldwide. Will these advanced treatments exacerbate existing disparities in access to quality care?

One patient in France has already made remarkable progress with PRIMA, finishing a 300-page novel and drawing an impressive sketch of the Sydney Opera House. While testimonials like these are heartening, they should not distract from the pressing question of equity. Those who benefit most from these technologies may be those who can afford them.

The development of bio-hybrid brain sensors is also on the horizon, with Science Corporation working closely with Dr. Murat Günel at Yale Medical School to develop procedures for human trials. This research holds immense promise but must be approached with caution. As Hodak acknowledged, a sustainable business model is crucial for long-term success – but this should not come at the expense of accessibility.

The commercialization of PRIMA will also raise questions about reimbursement and healthcare policy. Science Corporation is currently discussing reimbursement rates with healthcare providers in Europe, a process that will undoubtedly be contentious. The company’s goal to make PRIMA more portable and power-efficient may prove challenging given the complexity of the technology.

As these groundbreaking technologies move forward, it’s essential to prioritize not only innovation but also equity. We must ensure that those who benefit most from these developments are not just the privileged few but also the marginalized and underserved populations worldwide. Only then can we truly say that we’re making progress toward a more inclusive future for all.

The EU approval of Science Corporation’s vision-restoring chip has sparked hope in millions, but it’s up to us to ensure that this promise is fulfilled without exacerbating existing disparities. The time for action is now – and it’s not just about the technology itself, but also about who gets to access it.